Gene expression profiling to predict the risk of locoregional recurrence in breast cancer

Publication Name: Cancer Research

Author(s): C.A. Drukker, M.V. Nijenhuis, S.G.Elias, J. Wesseling, N.S. Russell, P. Whitworth, R. Patel, F. de Snoo, L.J. van’t Veer, P.D. Beitsch, E.J.Th. Rutgers

The 70-­‐gene signature is able to predict the risk of locoregional recurrence. We observed a significantly lower incidence of locoregional recurrence in patients with a low risk 70-­‐gene signature result compared to those with high risk 70-­‐gene signature result, independent of known risk factors. Patients with high risk 70-­‐gene signature cancers are eligible for extensive adjuvant treatment (radiotherapy, chemotherapy and/or endocrine therapy) to reduce the risk of distant as well as locoregional recurrence. Patients with low risk 70-­‐gene signature cancers are eligible for more limited local treatment strategies.

See Poster